Skip to main content
TipRanks
Go Ultimate75% OFF

Kringle Pharma, Inc. (4884) AI Stock Analysis

0 Followers
JP:4884

Kringle Pharma, Inc.

(TSE/TYO:4884)

Select Model
Rating:50.5Neutral
Price Target:JPY 558.00â–²(0.18% Upside)
Action:reiterated
Date:11/14/26

The overall score of 50.5 reflects a company with a stable, debt-free foundation but significant operational risks. The primary strength is the strong balance sheet, which provides a runway. The most significant weaknesses are the deep net losses and heavy cash burn, which are only partially offset by a recent surge in revenue. Moderately bullish technical trends provide some support, but the negative P/E ratio underscores the lack of current profitability.

Positive Factors
High Gross MarginThe approximately 84% gross margin indicates strong economics on revenue already generated and leaves meaningful room to cover operating costs if scale improves. While insufficient to offset current expenses today, this margin profile could support future profitability if revenue becomes more consistent.
Negative Factors
Persistent Net LossesPersistent, substantial net losses show that the current business has not yet converted its high gross margin into a sustainable earnings model. Continued losses can require repeated external funding, limit strategic flexibility, and make future profitability dependent on significant cost improvement or further revenue expansion.

Kringle Pharma, Inc. (4884) vs. iShares MSCI Japan ETF (EWJ)

-40%-20%0%20%40%60%80%JP:4884+32.94%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 4.79B
Dividend Yield
―
Average Volume (3M)
282.72K
Price to Earnings (P/E)
-5.3
Beta (1Y)
0.59
Revenue Growth
513.34%
EPS Growth
20.92%
Country
Japan
Employees
17
Sector
General
Sector Strength
55
Industry
Biotechnology

Kringle Pharma, Inc. Business Overview & Revenue Model

Company Description

Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious med...

Kringle Pharma, Inc. Financial Statement Overview

Summary

Financial performance is mixed. A pristine, debt-free balance sheet (Score 72) provides stability, but this is offset by deep unprofitability (Income Score 35) and significant cash burn (Cash Flow Score 30). The recent revenue surge is a positive signal, yet the overall financial health is pressured by unsustainable losses and cash outflows.

Income Statement

35Negative

Balance Sheet

72Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMSep 2026Sep 2025Sep 2024Sep 2023Sep 2022
Income Statement
Total Revenue341.47M442.92M72.22M80.04M69.25M391.83M
Gross Profit234.20M372.54M72.22M00303.42M
EBITDA-806.45M-813.45M-909.45M-817.88M-888.76M-426.17M
Net Income-808.44M-813.64M-916.25M-756.45M-854.15M-331.83M
Balance Sheet
Total Assets2.00B1.98B2.08B2.76B2.62B3.21B
Cash, Cash Equivalents and Short-Term Investments1.70B1.68B1.62B2.31B2.14B2.76B
Total Debt000000
Total Liabilities744.51M810.41M770.11M648.92M596.95M419.50M
Stockholders Equity1.25B1.17B1.31B2.11B2.02B2.79B
Cash Flow
Free Cash Flow000-661.17M-689.10M15.80M
Operating Cash Flow-755.78M-563.22M-755.78M-661.17M-689.10M15.80M
Investing Cash Flow-154.01M-16.48M-154.01M-121.36M-120.88M-254.38M
Financing Cash Flow84.14M643.15M84.14M838.23M69.16M603.11M

Kringle Pharma, Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price557.00

Price Trends

50DMA525.26Positive
100DMA439.31Positive
200DMA424.15Positive

Market Momentum

MACD-6.31Positive
RSI52.30Neutral
STOCH59.90Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Positive. The current price of 557.00 is below the 20-day moving average (MA) of 563.30, above the 50-day MA of 525.26, and above the 200-day MA of 424.15, indicating a neutral trend. The MACD of -6.31 indicates Positive momentum. The RSI at 52.30 is Neutral, neither overbought nor oversold. The STOCH value of 59.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4884.

Kringle Pharma, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4884 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4884JP:488451NeutralJPY 4.79B-5.26――513.34%20.92%
JP:4587JP:458748NeutralJPY 138.26B-47.73-5.85%―14.25%50.07%
JP:4598JP:459842NeutralJPY 1.25B-0.45―――20.94%
JP:4571JP:457141NeutralJPY 6.10B-4.20-39.57%―48.92%-46.91%
JP:4591JP:459140UnderperformJPY 3.31B-2.63―――9.55%
JP:4881JP:488138UnderperformJPY 1.98B-1.13――-27.93%22.36%

* General Sector Average

Performance Comparison

-50%0%50%JP:4884JP:4587JP:4571JP:4591JP:4598JP:4881Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4884 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4884Kringle Pharma, Inc.557.00128.0029.84%
JP:4587Peptidream 1065.00-518.50-32.74%
JP:4571NanoCarrier Co., Ltd.67.00-83.00-55.33%
JP:4591Ribomic, Inc.58.00-26.00-30.95%
JP:4598Delta-Fly Pharma, Inc.62.00-486.00-88.69%
JP:4881FunPep Company Limited39.00-50.00-56.18%

Kringle Pharma, Inc. Corporate Events

Kringle Pharma Wins FDA IND Clearance for Spinal Cord Injury Drug

Oct 19, 2026

Kringle Pharma has secured clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for oremepermin alfa, a recombinant human hepatocyte growth factor therapy for acute spinal cord injury. The decision allows...

Kringle Pharma Seeks U.S. Phase 3 Trial for Spinal Cord Injury Drug

Sep 24, 2026

Kringle Pharma has submitted an Investigational New Drug application to the U.S. FDA seeking to initiate a Phase 3 clinical trial of oremepermin alfa, a recombinant human hepatocyte growth factor, for the treatment of acute spinal cord injury in the...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026